Banco BTG Pactual S.A. Buys New Position in Insmed Incorporated (NASDAQ:INSM)

Banco BTG Pactual S.A. purchased a new position in Insmed Incorporated (NASDAQ:INSM) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 8,240 shares of the biopharmaceutical company’s stock, valued at approximately $576,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Jennison Associates LLC grew its stake in shares of Insmed by 0.6% in the 4th quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock worth $53,424,000 after purchasing an additional 4,560 shares during the last quarter. Capital CS Group LLC bought a new stake in Insmed during the fourth quarter worth approximately $586,000. Orion Portfolio Solutions LLC grew its position in Insmed by 48.5% in the third quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock worth $2,050,000 after buying an additional 9,170 shares during the last quarter. Ally Bridge Group NY LLC increased its holdings in shares of Insmed by 16.9% in the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock valued at $11,011,000 after buying an additional 21,833 shares in the last quarter. Finally, Vestal Point Capital LP lifted its position in shares of Insmed by 113.3% during the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after acquiring an additional 850,000 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. boosted their target price on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Stifel Nicolaus cut their price target on shares of Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Wells Fargo & Company raised their price objective on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. UBS Group boosted their target price on shares of Insmed from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Finally, Truist Financial raised their target price on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat, Insmed presently has an average rating of “Moderate Buy” and an average target price of $94.00.

Insmed Trading Down 1.1 %

Shares of NASDAQ INSM opened at $78.54 on Wednesday. The business has a 50 day simple moving average of $77.84 and a 200 day simple moving average of $73.89. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The stock has a market cap of $14.22 billion, a price-to-earnings ratio of -14.05 and a beta of 1.28. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The business had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, research analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50. Following the transaction, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at approximately $27,079,091.58. This trade represents a 5.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Sara Bonstein sold 3,470 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $65.70, for a total value of $227,979.00. Following the transaction, the chief financial officer now owns 114,736 shares in the company, valued at approximately $7,538,155.20. This trade represents a 2.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 550,957 shares of company stock worth $42,992,528 over the last three months. Corporate insiders own 4.60% of the company’s stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.